215 related articles for article (PubMed ID: 24440167)
1. A randomized double blind, placebo controlled phase 2 trial of BIIL 284 BS (an LTB4 receptor antagonist) for the treatment of lung disease in children and adults with cystic fibrosis.
Konstan MW; Döring G; Heltshe SL; Lands LC; Hilliard KA; Koker P; Bhattacharya S; Staab A; Hamilton A;
J Cyst Fibros; 2014 Mar; 13(2):148-55. PubMed ID: 24440167
[TBL] [Abstract][Full Text] [Related]
2. BIIL 284 reduces neutrophil numbers but increases P. aeruginosa bacteremia and inflammation in mouse lungs.
Döring G; Bragonzi A; Paroni M; Aktürk FF; Cigana C; Schmidt A; Gilpin D; Heyder S; Born T; Smaczny C; Kohlhäufl M; Wagner TO; Loebinger MR; Bilton D; Tunney MM; Elborn JS; Pier GB; Konstan MW; Ulrich M
J Cyst Fibros; 2014 Mar; 13(2):156-63. PubMed ID: 24183915
[TBL] [Abstract][Full Text] [Related]
3. Leukotriene receptor antagonists in children with cystic fibrosis lung disease : anti-inflammatory and clinical effects.
Schmitt-Grohé S; Zielen S
Paediatr Drugs; 2005; 7(6):353-63. PubMed ID: 16356023
[TBL] [Abstract][Full Text] [Related]
4. Clinical trial of a leucotriene B4 receptor antagonist, BIIL 284, in patients with rheumatoid arthritis.
Díaz-González F; Alten RH; Bensen WG; Brown JP; Sibley JT; Dougados M; Bombardieri S; Durez P; Ortiz P; de-Miquel G; Staab A; Sigmund R; Salin L; Leledy C; Polmar SH
Ann Rheum Dis; 2007 May; 66(5):628-32. PubMed ID: 17170051
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of leukotriene B4-induced CD11B/CD18 (Mac-1) expression by BIIL 284, a new long acting LTB4 receptor antagonist, in patients with rheumatoid arthritis.
Alten R; Gromnica-Ihle E; Pohl C; Emmerich J; Steffgen J; Roscher R; Sigmund R; Schmolke B; Steinmann G
Ann Rheum Dis; 2004 Feb; 63(2):170-6. PubMed ID: 14722206
[TBL] [Abstract][Full Text] [Related]
6. EMPIRE-CF: A phase II randomized placebo-controlled trial of once-daily, oral acebilustat in adult patients with cystic fibrosis - Study design and patient demographics.
Elborn JS; Ahuja S; Springman E; Mershon J; Grosswald R; Rowe SM
Contemp Clin Trials; 2018 Sep; 72():86-94. PubMed ID: 30056216
[TBL] [Abstract][Full Text] [Related]
7. Long-term treatment with oral N-acetylcysteine: affects lung function but not sputum inflammation in cystic fibrosis subjects. A phase II randomized placebo-controlled trial.
Conrad C; Lymp J; Thompson V; Dunn C; Davies Z; Chatfield B; Nichols D; Clancy J; Vender R; Egan ME; Quittell L; Michelson P; Antony V; Spahr J; Rubenstein RC; Moss RB; Herzenberg LA; Goss CH; Tirouvanziam R
J Cyst Fibros; 2015 Mar; 14(2):219-27. PubMed ID: 25228446
[TBL] [Abstract][Full Text] [Related]
8. In vitro and in vivo pharmacological characterization of BIIL 284, a novel and potent leukotriene B(4) receptor antagonist.
Birke FW; Meade CJ; Anderskewitz R; Speck GA; Jennewein HM
J Pharmacol Exp Ther; 2001 Apr; 297(1):458-66. PubMed ID: 11259574
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of ataluren in patients with nonsense-mutation cystic fibrosis not receiving chronic inhaled aminoglycosides: The international, randomized, double-blind, placebo-controlled Ataluren Confirmatory Trial in Cystic Fibrosis (ACT CF).
Konstan MW; VanDevanter DR; Rowe SM; Wilschanski M; Kerem E; Sermet-Gaudelus I; DiMango E; Melotti P; McIntosh J; De Boeck K;
J Cyst Fibros; 2020 Jul; 19(4):595-601. PubMed ID: 31983658
[TBL] [Abstract][Full Text] [Related]
10. Empire-CF study: A phase 2 clinical trial of leukotriene A4 hydrolase inhibitor acebilustat in adult subjects with cystic fibrosis.
Elborn JS; Konstan MW; Taylor-Cousar JL; Fajac I; Horsley A; Sutharsan S; Aaron SD; Daines CL; Uluer A; Downey DG; Lucidi VV; Ahuja S; Springman E; Mershon J; Grosswald R; Rowe SM;
J Cyst Fibros; 2021 Nov; 20(6):1026-1034. PubMed ID: 34538755
[TBL] [Abstract][Full Text] [Related]
11. Repeated adeno-associated virus serotype 2 aerosol-mediated cystic fibrosis transmembrane regulator gene transfer to the lungs of patients with cystic fibrosis: a multicenter, double-blind, placebo-controlled trial.
Moss RB; Rodman D; Spencer LT; Aitken ML; Zeitlin PL; Waltz D; Milla C; Brody AS; Clancy JP; Ramsey B; Hamblett N; Heald AE
Chest; 2004 Feb; 125(2):509-21. PubMed ID: 14769732
[TBL] [Abstract][Full Text] [Related]
12. Rationale and design of a randomized trial of home electronic symptom and lung function monitoring to detect cystic fibrosis pulmonary exacerbations: the early intervention in cystic fibrosis exacerbation (eICE) trial.
Lechtzin N; West N; Allgood S; Wilhelm E; Khan U; Mayer-Hamblett N; Aitken ML; Ramsey BW; Boyle MP; Mogayzel PJ; Goss CH
Contemp Clin Trials; 2013 Nov; 36(2):460-9. PubMed ID: 24055998
[TBL] [Abstract][Full Text] [Related]
13. Digitoxin for Airway Inflammation in Cystic Fibrosis: Preliminary Assessment of Safety, Pharmacokinetics, and Dose Finding.
Zeitlin PL; Diener-West M; Callahan KA; Lee S; Talbot CC; Pollard B; Boyle MP; Lechtzin N
Ann Am Thorac Soc; 2017 Feb; 14(2):220-229. PubMed ID: 28006108
[TBL] [Abstract][Full Text] [Related]
14. Long-term azithromycin for Indigenous children with non-cystic-fibrosis bronchiectasis or chronic suppurative lung disease (Bronchiectasis Intervention Study): a multicentre, double-blind, randomised controlled trial.
Valery PC; Morris PS; Byrnes CA; Grimwood K; Torzillo PJ; Bauert PA; Masters IB; Diaz A; McCallum GB; Mobberley C; Tjhung I; Hare KM; Ware RS; Chang AB
Lancet Respir Med; 2013 Oct; 1(8):610-620. PubMed ID: 24461664
[TBL] [Abstract][Full Text] [Related]
15. KB001-A, a novel anti-inflammatory, found to be safe and well-tolerated in cystic fibrosis patients infected with Pseudomonas aeruginosa.
Jain R; Beckett VV; Konstan MW; Accurso FJ; Burns JL; Mayer-Hamblett N; Milla C; VanDevanter DR; Chmiel JF;
J Cyst Fibros; 2018 Jul; 17(4):484-491. PubMed ID: 29292092
[TBL] [Abstract][Full Text] [Related]
16. Effect of oral glycine on the clinical, spirometric and inflammatory status in subjects with cystic fibrosis: a pilot randomized trial.
Vargas MH; Del-Razo-Rodríguez R; López-García A; Lezana-Fernández JL; Chávez J; Furuya MEY; Marín-Santana JC
BMC Pulm Med; 2017 Dec; 17(1):206. PubMed ID: 29246256
[TBL] [Abstract][Full Text] [Related]
17. Safety and efficacy of lenabasum in a phase 2 randomized, placebo-controlled trial in adults with cystic fibrosis.
Chmiel JF; Flume P; Downey DG; Dozor AJ; Colombo C; Mazurek H; Sapiejka E; Rachel M; Constantine S; Conley B; Dgetluck N; Dinh Q; White B; Elborn JS;
J Cyst Fibros; 2021 Jan; 20(1):78-85. PubMed ID: 33011099
[TBL] [Abstract][Full Text] [Related]
18. Inhaled hypertonic saline in infants and children younger than 6 years with cystic fibrosis: the ISIS randomized controlled trial.
Rosenfeld M; Ratjen F; Brumback L; Daniel S; Rowbotham R; McNamara S; Johnson R; Kronmal R; Davis SD;
JAMA; 2012 Jun; 307(21):2269-77. PubMed ID: 22610452
[TBL] [Abstract][Full Text] [Related]
19. A phase 3, multi-center, multinational, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of levofloxacin inhalation solution (APT-1026) in stable cystic fibrosis patients.
Flume PA; VanDevanter DR; Morgan EE; Dudley MN; Loutit JS; Bell SC; Kerem E; Fischer R; Smyth AR; Aaron SD; Conrad D; Geller DE; Elborn JS
J Cyst Fibros; 2016 Jul; 15(4):495-502. PubMed ID: 26852040
[TBL] [Abstract][Full Text] [Related]
20. Effect of azithromycin on pulmonary function in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa: a randomized controlled trial.
Saiman L; Anstead M; Mayer-Hamblett N; Lands LC; Kloster M; Hocevar-Trnka J; Goss CH; Rose LM; Burns JL; Marshall BC; Ratjen F;
JAMA; 2010 May; 303(17):1707-15. PubMed ID: 20442386
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
